EYLEA® READY-TO-USE INJECTOR WITH SOLUTION FOR INTRAVITREAL INJECTION 40 mg/mL

It is administered by intravitreal injection.

Active ingredient: Each 1 mL solution contains 40 mg aflibercept.

Excipients: Polysorbate 20, sodium phosphate monobasic monohydrate (for pH adjustment), sodium phosphate dibasic heptahydrate (for pH adjustment), sodium chloride, sucrose, water for injection.

Before you start using this medicine, read this INSTRUCTIONS FOR USE carefully, because it contains important information for you.

EYLEA is a sterile, clear, colorless to pale yellow, iso-osmotic (having the same osmotic pressure as the inside of your eye) aqueous solution for administration by injection into the eye.

In patients with branch retinal vein occlusion (RVDO); A blockage occurs in one or more branches of the main blood vessels that carry blood away from the retina. In response to this situation, VEGF levels increase, causing fluid leakage into the retina and resulting macular edema.

In patients with central retinal vein occlusion (CRVO), a blockage occurs in the main blood vessel that carries blood away from the retina. In response to this situation, VEGF levels increase, causing fluid leakage into the retina and resulting swelling in the macula (macular degeneration); This is called macular edema (swelling in the back of the eye). When the macula swells with fluid, central vision becomes blurred.

Diabetic macular edema (DME) is retinal swelling that occurs in diabetic patients due to fluid leakage from blood vessels within the macula. The macula is the part of the retina responsible for good vision. When the macula swells with fluid, central vision becomes blurred.

EYLEA has been shown to reduce the formation of abnormal new blood vessels in the eye and the amount of fluid and blood leaking into the retina. EYLEA helps prevent the progression of vision loss associated with wet AMD, CRVO, RVDO, DME and myopic CNV, and provides improvement in vision loss in many patients.

Instructions for proper use and dosage/frequency of administration

The recommended dose is 2 mg aflibercept (0.05 mL).

In patients with wet AMD, treatment is recommended as a single injection once a month in three consecutive doses followed by a single injection every two months.

At your physician’s discretion regarding visual and/or anatomical results, your treatment interval may be maintained at two months or extended using a treat-and-extend dosing regimen, in which injection intervals may be extended in 2- or 4-week increments to maintain stable visual and/or anatomical results.

If your condition worsens, injection intervals may be shortened.

Like all medicines, side effects may occur in people who are sensitive to the ingredients contained in EYLEA.

If any of the following occur, stop using EYLEA and IMMEDIATELY inform your doctor or go to the emergency department of your nearest hospital.

There is a possibility of developing an allergic reaction (hypersensitivity with symptoms such as itching, rash, eyelid edema).

These are all serious side effects. If you have any of these, you may need urgent medical attention or hospitalization.

If you notice any of the following, immediately inform your doctor or go to the emergency department of your nearest hospital.

⚠️ Disclaimer: The information provided on this website is for informational purposes only and does not substitute professional medical advice. Always consult a healthcare provider before using any medication.